Angiotensin ii, from vasoconstrictor to growth factor: A paradigm shift

Circulation Research

Volumn 114, Issue 5, 2014, Pages 754-757

  Vukelic, Sasa ^a   Griendling, Kathy K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CALCIUM ION; CAPTOPRIL; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; OCTAPEPTIDE; PHOSPHOLIPASE C; PLATELET DERIVED GROWTH FACTOR; VASOCONSTRICTOR AGENT;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CONGESTIVE HEART FAILURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; VASOCONSTRICTION;

EID: 84896757635     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.303045     Document Type: Review

References (33)

1. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
2. Tigerstedt R, Bergman PQ. Niere und kreislauf1. Skandinavisches Archiv Fr Physiologie. 1898;8:223-271.
3. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-379.
4. Fasciolo JC, Leloir LF, Muoz JM, Braun-Menendez E. On the specificity of renin. Science. 1940;92:554-555.
5. Page IH, Helmer OM, Kohlstaedt KG, Fouts PJ, Kempf GF. Reduction of arterial blood pressure of hypertensive patients and animals with extracts of kidneys. J Exp Med. 1941;73:7-41.
6. Braun-Menendez E, Page IH. Suggested Revision of Nomenclature- Angiotensin. Science. 1958;127:242.
7. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9-20.
8. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science. 1977;196:441-444.
9. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977;238:880-882.
10. Corea L, Bentivoglio M, Verdecchia P. Low-dose captopril therapy in mild and moderate hypertension. Randomized comparison of twice daily vs three times daily doses. Hypertension. 1983;5:III157-159.
11. Owens GK. Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat. Circ Res. 1985;56:525-536.
12. Borer JS. Angiotensin-converting enzyme inhibition: A landmark advance in treatment for cardiovascular diseases. Eur Heart J. Suppl. 2007;9:E2-E9.
13. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension. 1987;9:178-187.
14. Holycross BJ, Peach MJ, Owens GK. Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro. J Vasc Res. 1993;30:80-86.
15. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
16. Turla MB, Thompson MM, Corjay MH, Owens GK. Mechanisms of angiotensin II-and arginine vasopressin-induced increases in protein synthesis and content in cultured rat aortic smooth muscle cells. Evidence for selective increases in smooth muscle isoactin expression. Circ Res. 1991;68:288-299.
17. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116:36-48.
18. Yoshida T, Hoofnagle MH, Owens GK. Myocardin and Prx1 contribute to angiotensin II-induced expression of smooth muscle alpha-actin. Circ Res. 2004;94:1075-1082.
19. Hoofnagle MH, Neppl RL, Berzin EL, Teg Pipes GC, Olson EN, Wamhoff BW, Somlyo AV, Owens GK. Myocardin is differentially required for the development of smooth muscle cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 2011;300:H1707-H1721.
20. Merkel LA, Rivera LM, Colussi DJ, Perrone MH. Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun. 1993;192:1319-1326.
21. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: A new activity for platelet-derived growth factor. Science. 1986;232:87-90.
22. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2nd, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
23. Tsuda T, Kawahara Y, Shii K, Koide M, Ishida Y, Yokoyama M. Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells. FEBS Lett. 1991;285:44-48.
24. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
25. LeJemtel TH, Keung E, Frishman WH, Ribner HS, Sonnenblick EH. Hemodynamic effects of captopril in patients with severe chronic heart failure. Am J Cardiol. 1982;49:1484-1488.
26. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation. 1980;61:931-937.
27. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol. 1988;62:60A-66A.
28. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
29. Van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088-2097.
30. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med. 1996;156:286.
31. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239.
32. Mancia G, Fagard R, Narkiewicz K, Redan J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, List of authors Task Force. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31:1925-1938.
33. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.